Download presentation
Presentation is loading. Please wait.
Published byJordan Copeland Modified over 6 years ago
1
CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture–Based Tissue Genomic Profiling and ctDNA Assays
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 2, Pages e19-e20 (February 2017) DOI: /j.jtho Copyright © Terms and Conditions
2
Figure 1 Antitumor response to crizotinib after ROS1 fusion identified on tissue and circulating tumor DNA hybrid capture–based assay. (left) Computed tomography scan of chest/abdomen at diagnosis. Pretreatment tumor measured 8.8 × 5 cm. (right) Computed tomography scan with contrast after 8 weeks of crizotnib. Residual lesion is primarily pleural effusion with diminished size of left lower lobe mass with improved left lower lobe aeration and resolution of left lower lobe bronchial and pulmonary vascular occlusion. Journal of Thoracic Oncology , e19-e20DOI: ( /j.jtho ) Copyright © Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com Inc.
All rights reserved.